Spiroxasone (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name) is a synthetic, steroidal antimineralocorticoid of the spirolactone group which was developed as a diuretic and antihypertensive agent but was never marketed.[1][2] It was synthesized and assayed in 1963.[1] The drug is 7α-acetylthiospirolactone with the ketone group removed from the C17α spirolactone ring.[1] Similarly to other spirolactones like spironolactone, spiroxasone also possesses antiandrogen activity.[3][4]

References

  1. ^ a b c Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 1114–. ISBN 978-1-4757-2085-3.
  2. ^ Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 261–. ISBN 978-94-011-4439-1.
  3. ^ Progress in Medicinal Chemistry. Elsevier. 1 January 1979. pp. 69–. ISBN 978-0-08-086264-4. Spiroxasone [...] is also an anti-androgen [379].
  4. ^ Rasmusson GH, Chen A, Reynolds GF, Patanelli DJ, Patchett AA, Arth GE (November 1972). "Antiandrogens. 2',3' -Tetrahydrofuran-2'spiro-17-(1,2 -methylene-4-androsten-3-ones)". Journal of Medicinal Chemistry. 15 (11): 1165–1168. doi:10.1021/jm00281a018. PMID 4654667.